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Background:, Endoscopic! surveillance! for! nonVdysplastic! Barrett’s! esophagus! is!
contentious!and!its!costVeffectiveness!unclear.!!
Objective:!To!perform!an!economic!analysis!of!endoscopic!surveillance!strategies.!









Results:, Compared! with! no! surveillance,! surveillance! produced! an! estimated!
incremental! cost! per!QALY! ratios! of! $60,858.! This!was! reduced! to! $38,307!when!








esophagus,! endoscopic! surveillance! of! patients! with! nonVdysplastic! Barrett’s!
esophagus! is!unlikely! to!be!costVeffective! for! the!majority!of! patients!and!depends!




Take, home,message:! Endoscopic! surveillance! of! all! patients! with! nonVdysplastic!
Barrett’s! esophagus! may! not! be! costVeffective.! Although! the! biomarker! strategy!













curable! stages,! and! is! endorsed!by! several! leading! bodies! in! the!UK!and!US[5V6]!




program! varies!widely! from!1/285! to! 1/52! patientVyears,[10V15]! or! 0.2%! to! 2%!per!
year[1].! However,! advocates! of! surveillance! suggest! it! is! the! only! option! for! early!
detection,! and! since! adenocarcinoma! occurs! through! a! known! sequence! of!





poor! quality! evidence[16].! Clinical! practice! has! also! improved,! notably! with! lower!
mortality! rates! reported! for! esophagectomy! and! greater! use! of! less! invasive!
endoscopic! techniques.! Some! previous! studies! suggest! surveillance! is! not! costV
effective!under!any!scenario!tested[17V18],!while!others!conclude!that!surveillance!is!
economically! acceptable! under! certain! conditions! (for! example,! when! the!
surveillance!interval!is!lengthened[19V20]).!!Hampering!this!work!has!been!a!lack!of!
evidence! for! crucial! inputs! for!modeling! (e.g.,! quality! of! life,! proportion! of! patients!
progressing! among! dysplasia! grades).! Moreover,! analyses! have! not! adequately!
scrutinized!the!clinical!uncertainty!of!alternative!management!options!for!early!stage!
cancer[16]! such! as! endoscopic! procedures! [16,! 21].! Mortality! rates! for!
oesophagectomy!are!also!improving!in!specialist!centers,!and!recent!epidemiological!
studies! have! produced! more! rigorous! estimates! of! the! natural! history! of! Barrett’s!
esophagus[22].!!
!








surveillance,! and! exclusion! of! patients! at! low! risk,! thereby! improving! costV
effectiveness.! To! date! biomarkers! which! facilitate! this! approach! are! unproven,!
although! past! work! has! shown! a! combination! of! critical! abnormalities! within! the!
tumorVsuppressor!genes!TP53!and!CDKN2A,!as!well!as!DNA!content!abnormalities!
(tetraploidy! and! aneuploidy),! are! associated! with! a! high! risk! of! cancer!






surveillance! for! nonVdysplastic!Barrett’s! esophagus!within!a! structured! surveillance!
program.!Updated!epidemiological!data!and!observational!study!findings!were!used!
in! the! modeled! analysis! and! the! model! also! evaluated! the! effect! of! adding! a!
hypothetical! biomarker! test! to! identify! highVrisk! patients.! Although! biomarkers! are!
untested! in! clinical! practice,! the! considerable! current! effort! to! identify! predictive!
biomarkers! for!Barrett’s!esophagus!suggests! that!such!markers!will!at!some!stage!









and! 3)! endoscopic! surveillance! modified! by! a! hypothetical! biomarker! test.!
Endoscopic! surveillance! intervals! were! based! on! UK! British! Society! of!
Gastroenterology! guidelinese! 2Vyearly! for! nonVdysplastic! Barrett’s! esophagus! with!
intestinal! metaplasia,! and! 6Vmonthly! for! Barrett’s! esophagus! with! lowVgrade!
dysplasia[25].! ! It! was! assumed! that! appropriate! scheduling! of! endoscopies! was!
achieved,!mucosal!biopsies!were!collected!using!the!Seattle!protocol!(i.e.!4Vquadrant!
biopsies! at! 2cm! intervals! with! histopathology! checked! by! two! pathologists! if! high!
grade!dysplasia!was! identified)[26],! diagnoses!of!Barrett’s! esophagus!or! dysplasia!
6"
"
were! accurate,! and! all! patients! attended! their! scheduled! appointments.! The! data!
used! to! determine! the! clinical! outcomes! was! derived! from! a! database! which!
underpins! a! managed! Barrett’s! esophagus! surveillance! program! in! Adelaide,!





A! health! state! transition! Markov! Model! was! constructed! in! TreeAge! Pro! 2011!
(TreeAge! Software! Inc,! Williamstown,! MA,! USA)! and! designed! to! synthesize!
published! evidence! and! data! from! the! primary! patientVlevel! dataset.! A! twoVstage!
approach!was!taken!where!clinical!pathways!and!treatments!following!a!diagnosis!of!
esophageal!adenocarcinoma!were!first!analyzed!(the!‘treatment!model’)[27]!and!then!
integrated!within!a! larger!surveillance!model! focusing!on! the!parameters!pertaining!
to! surveillance! activities! (the! ‘surveillance!model’)! (Figure! 1)! (Supplementary!File).!
Briefly,! the!treatment!model! is!a!5Vyear!decisionVanalytic!model!and!traces!patients!
from!a!diagnosis!of!high!grade!dysplasia!or!adenocarcinoma.!!Treatment!pathways!
were!determined!by! cancer!T! stage,!with!T1!stage!divided! into!T1a!and!T1b.!The!
use! of! T! stage! rather! than! TNM! stage! was! necessary! because! T! stage! can! be!
determined!for!all!patients!undergoing!endoscopic!and!surgical!therapy,!but!N!stage!
can!only!be!identified!accurately!following!surgical!resection,!and!can!be!distorted!by!
neoadjuvant! treatment! with! chemotherapy! or! chemoradiotherapy., The! main!
treatments! included!esophagectomy,! endoscopic!mucosal! resection/radiofrequency!
ablation,!radiotherapy,!chemotherapy,!or!watchful!waiting.!!Prospective!data!from!the!





The! surveillance!model! tracked! a! hypothetical! cohort! through! 6Vmonthly! cycles! to!
examine!the!health!and!cost!outcomes!of!individuals!entering!a!Barrett’s!esophagus!
surveillance!program.!To!reflect!real!life,!most!members!entered!surveillance!with!a!
confirmed! diagnosis! of! nonVdysplastic! Barrett’s! esophagus! (95%),! but! with! 4%!





including:! Barrett’s! esophagus! free,! nonVdysplastic! Barrett’s! esophagus,! lowVgrade!
dysplasia,! highVgrade! dysplasia,! esophageal! adenocarcinoma! (apportioned! by! T1,!
T2,! T3,! T4! stages! and! distant! metastases)! and! allVcause! death! (Figure! 1).!
Individuals!could!move!between!these!mutually!exclusive!health!states,!once!every!
six! months,! or! remain! in! the! same! state.! If! a! person! developed! esophageal!
adenocarcinoma,! they! were! subject! to! the! 5Vyear! treatment! pathways,! associated!
cost,!quality!of!life!and!survival!outcomes!according!to!T!stage!within!the!‘treatment!
model’.!For!example,!surgical!mortality!rates!from!esophageal!cancer!ranged!from!2V
6%!depending! on!T! stage! ([27],! Supplementary!File).! Key! outcomes! of! the!model!
included!incremental!costs!and!qualityVadjusted!life!years!(QALYS).!!
!
Treatments! for! highVgrade! dysplasia! or! esophageal! adenocarcinoma! were!
constructed!with!particular!attention! to!different!clinical!algorithms! for!T1a!and!T1b!
tumors,! inclusion! of! postVoperative!mortality,! inclusion! of! lessVinvasive! endoscopic!
treatments! (endoscopic! mucosal! resection! and! radiofrequency! ablation)" and!
validated! structurally! by! clinicians[27].! ! Individuals! who! remained! alive! after! five!
years!following!a!diagnosis!of!highVgrade!dysplasia!or!esophageal!adenocarcinoma!
received! onVgoing! endoscopy! every! six! months! for! three! years! and! annually!
thereafter.! These! individuals! were! assumed! to! die! eventually! of! other! causes.!
Individuals!may!die!of!any!cause!at!any!time!during!the!model!from!any!health!state!






Pivotal! to! the! model! are! the! progression! rates! from! nonVdysplastic! Barrett’s!
esophagus! to! adenocarcinoma,! and! lowVgrade! dysplasia! to! adenocarcinoma,!
creating! the! model’s! health! state! transition! probabilities.! A! literature! search! was!
undertaken!to!extract!the!most!recent!and!relevant!data!estimates!(Table!1).!Large!




Barrett’s! esophagus! to! adenocarcinoma,! the! estimate! of! 0.33%! per! year! was!
selected! from! a!metaVanalysis! by! Desai! et* al.! 2011! on! a! subset! of! higherVquality!
studies.! This! pooled! estimate! excluded! studies! capturing! prevalent! cases! of!
adenocarcinoma!and!highVgrade!dysplasia!and!included!those!with!greater!than!five!
years!followVup[31].!This!estimate!was!also!very!similar!to!those!presented!in!recent!
large! observational! studies! in! Northern! Ireland! 0.27%[28],! The! Netherlands!
0.39%[30],! but! somewhat! higher! than! reported!by!HvidVJensen!et* al.! 2011,! 0.12%!
(95%CI:! 0.09%,! 0.15%),! although! this! latter! study! included! patients!with! columnar!
epithelium!without! intestinal!metaplasia[22].!We! tested! the! results! using! estimates!
0.09%! and! 0.5%! in! a! sensitivity! analysis.! We! assessed! the! literature! reporting!
corresponding! progression! rates! for! patients! within! a! surveillance! program! with! a!
focus!on!more!recent!studies!(Table!2).!Our!estimates!were!taken!from!a!prospective!




wellVmanaged! surveillance! program! compliant! with! UK! recommendations! [26,! 32]!




derived! rates! accurately! reproduced! the! incidences! and! cumulative! incidences! of!
lowV! and! highVgrade! dysplasia! and! esophageal! adenocarcinoma! and! gastroV
esophageal!junction!carcinoma!observed!in!the!surveillance!program.!The!rates!and!
cumulative! incidences! were! then! verified! in! the! TreeAge! model.! The! high!


















inflated! to! 2011! dollars! using! the! Australian! Consumer! Price! Index.! Results! are!
presented! in! US! dollars! (AUD! 1! =! USD! 1)." Itemized! costs! for! surveillance! and!
biomarker!testing!are!provided!in!the!Supplementary!File.!Briefly,!for!the!surveillance!
program,!an!average!cost!per!person!was!calculated!as!the!sum!of!initial!endoscopy!
at! entry,! subsequent! endoscopies! (according! to! the! schedule! for! respective!
dysplasia! grade)! and! histopathology! testing.! Administration! costs! for! managing! a!
surveillance!program!were!also!calculated!per!person!and! included!staff,!database!
license,! letters/printing! and! phone! calls.! Biomarker! testing! included! costs! for! flow!
cytometric! cell! sorting,! gDNA! amplification,! PCRs,! staff! time! and!multiple! biopsies!
per! patient.!Costs! for! all! direct!medical! resources! involved! in! diagnosis,! treatment!
and! followVup! care! of! esophageal! cancer! were! derived! from! patientVlevel! data!
collected!within! the!Australian!Cancer!Study! (ACS)!over!several! years!via!medical!
chart!review[27,!38]!(Supplementary!File).!Resources!included!biopsies,!ultrasounds,!
imaging,! endoscopic! treatments! and! investigations,! hospitalizations,! inVhospital!
adverse!events,!chemotherapy,!radiotherapy,!monitoring,!stents!and!palliative!care.!
Proton!pump!inhibitor!medications!were!assumed!to!be!taken!by!all! individuals!and!
were! not! included! in! the! model! as! costs! were! not! expected! to! differ! across! the!
intervention! strategies.!Resources!were!valued!using!national! price! schedules!and!
public! hospital! clinical! costs! for! inpatient! surgical! stays.! The! mean! cost! of! an!
oesophagectomy! included! inVhospital! adverse! events! and! intensive! care! unit!









per! year! to! adjust! for! the! relative! value! of! present! costs! and! life! years.! The!
incremental! costVeffectiveness! ratios! (ICER)! were! calculated.! OneVway! sensitivity!
analyses! were! undertaken! where! each! parameter! was! varied! through! a! range! of!
plausible! values! (Table! 1)! and! changes! to! the! base! results! were! observed.! We!
varied!the!surveillance!frequency!(3V!or!5Vyearly!for!nonVdysplastic!Barrett’s,!annual!
for! lowVgrade! dysplasia),! the! starting! age! (55! years,! 60! years),! the! maximum!
surveillance!duration! (5,!10,!20!years)!and! the!discount! rate! (0%,!1.5%,!3.5%).!All!
other!model!parameters!were! tested!between!high!and! low!values! (Table!1)!using!
the!95%!confidence!intervals!where!available,!values!reported!in!the!literature,!or!±!
20%.!We! also! considered! the! cost! impact! on! the! results! when! we! increased! the!
proportion!of!patients!with!T1a!cancers! receiving!endoscopic! treatments! instead!of!
oesophagectomy!(to!90%,!from!a!base!case!of!50%).!Sensitivity!analyses!were!not!
performed! on! other! variables! relating! to! the! treatment! of! highVgrade! dysplasia! or!
esophageal!cancer!(e.g.,!esophageal!mortality!rates,!utility!values!for!cancer!stage,!
costs! of! chemoradiation)e! these! were! comprehensively! undertaken! in! previously!
published!analyses! [27]!and!will!have!negligible!effect!on!a!surveillance!population!
because! they! affect! a! small! proportion! of! individuals.! A! probabilistic! sensitivity!
analysis!was! also! performed! by! reVsampling! 5000! times! at! random! from!assigned!
probability! distributions! for! each! parameter! to! address! the! uncertainty! of! data!
estimates! simultaneously.! Gamma! distributions! were! used! for! costs! and! beta!




In! addition! to! the! standard! surveillance! model,! we! modified! and! reVevaluated! the!
Barrett’s!esophagus!surveillance!program!using!a!hypothetical!biomarker! test.!The!
’surveillance! with! biomarker’! strategy! parameters! was! based! on! the! procedures,!
methods,!and!outcomes!reported!by!Galipeau!et*al.!(2007)[23].!In!this!study,!patients!
with!Barrett’s! esophagus!were!evaluated!at! baseline! for!TP53!and!CDKN2A! (p16)!
alterations,! tetraploidy,! and! aneuploidy! using! sequencing,! loss! of! heterozygosity,!












the! progression! from! BE,! lowV! or! highVgrade! dysplasia! to! esophageal! cancer! was!
40.7%!sensitivity!and!98.0%!specificity.!Under!our!model,!patients!with!the!“positive!
biomarker! test”! were! assigned! to! receive! more! frequent! (6Vmonthly)! endoscopic!
surveillance.!Transition!rates!were!derived!by!iterating!a!hidden!Markov!model!(see!
below)! using! an!expectation–maximization! algorithm! to! generate! overall! expected!
rates!of!progression!(proportionally!adjusted!to!be!relative!to!our!overall!base!rates)!
to!cancer!and!dysplasia!for!positive!or!negative!tests[40].!Alternative!strategies!were!
also! examined!where:! 1)! patients!with! a! “positive! biomarker! test”! received! prompt!
radiofrequency! ablation! therapy! and! accrued! the! same! outcomes! as! patients! with!







Over! 30! years,! the! (discounted)! mean! cost! per! person! for! the! surveillance! alone!
strategy! was! $14,659,! compared! with! $11,087! for! surveillance! modified! by! a!
biomarker! test,! and! $5,226! for! no! surveillance.! The! corresponding! mean! QALYs!




for! surveillance! alone! and! $38,307! for! surveillance! modified! by! biomarker! testing!
(Table!3).!The!incremental!cost!per!QALY!was!improved!for!surveillance!modified!by!
a!biomarker!test!due!to!lower!costs!and!similar!QALYs!vs.!surveillance!alone,!arising!
from!a!higher!proportion!of! lowVrisk! individuals!with!a!negative! test! result! receiving!
no! further!surveillance.! In!a!comparison!of! ‘no!surveillance’! versus!patients! testing!
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positive! for!biomarkers!and!receiving! radiofrequency!ablation!or!no!surveillance! for!
those! testing! negative,! the! results! showed! that! ‘no! surveillance’!was! superior!with!
higher! QALYs! and! fewer! total! costs.! However,! if! patients! testing! positive! for!
biomarkers! received! 6Vmonthly! surveillance! while! patients! with! negative! tests!




nonVdysplastic!Barrett’s!esophagus! to!highVgrade!dysplasia,!and! from! lowV! to!highV
grade!dysplasia,!with!high!progression!rates!under!surveillance!leading!to!high!costV
effectiveness! ratios! (Table! 4).! Low! progression! estimates! for! all! nonVsurveillance!
states! also! increased! the! costVeffectiveness! ratios! substantially.! The! hypothetical!
increased! yield! of! highVgrade! dysplasia! found! with! positive! biomarker! tests! and!
subsequent!changes! in!management!also! influenced!the!ratios!markedly!(Table!4).!
Less! frequent! surveillance! endoscopies! improved! the! costVeffectiveness! of!
surveillance! substantially.! When! a! disutility! was! incorporated! for! individuals!
undergoing! surveillance,! the! ‘no! surveillance’! option! was! superior! to! surveillance!
alone!but!surveillance!with!a!biomarker! remained!costVeffective.!Finally,! the! results!
of! the! twoVway! sensitivity! analyses! show!surveillance!with! hypothetical! biomarkers!
would!be!preferred!at!current!estimates!of!progression!from!nonVdysplastic!Barrett’s!
esophagus! to! lowV! or! highVgrade! dysplasia,! under! no! surveillance! and! lower!









the! probability! that! surveillance! alone! was! costVeffective! compared! with! no!







Our! results! indicated! that! the! surveillance! alone! strategy,! as! presented! here,! is!
unlikely! to! be! costVeffective,! when! compared! with! no! surveillance.! ! This! result! is!
uncertain,! however,! due! to! the! volatility! in! the! model! that! results! from! small!
variations! in! the! progression! rates! between! dysplasia! grades! and! the! subsequent!
development! of! adenocarcinoma.! However,! the! costVeffectiveness! was! markedly!
improved!under!the!hypothetical!scenario!of!biomarker!testing,!with!acceptable!limits!
of! sensitivity! and! specificity,! which! serves! to! differentiate! surveillance! program!
participants! into! lowV! and! highVrisk! groups,! and! subsequently! with! more! targeted!
treatment!pathways!and!higher!proportions!of!preV!or!earlyVstage!cancers!detected.!
The! costVeffectiveness! of! an! alternative! biomarker! strategy! remained! favorable! if!
patients! testing!negative! for!biomarkers!did!not! receive!surveillance! in! the! first! five!
years! and! received! 2Vyearly! surveillance! thereafter." In! addition,! if! endoscopy!
surveillance!of!patients!with!nonVdysplastic!Barrett’s!esophagus!was!scheduled!less!
frequently,! either! 3V! or! 5Vyearly! and/or! annually! for! lowVgrade! dysplasia,! the! costV
effectiveness! of! surveillance! would! be! acceptable! in! most! health! systems.! This,!
however,! assumes! that! no! cancers! are! missed! or! progress! to! advanced! stage!
disease!and!there!is!only!limited!evidence!to!support!this![43].!
!!
Several! Markov! modeling! studies! using! ‘no! surveillance’! comparators! have!
concluded! the!additional! gains!during!surveillance!are!not! costVeffective[17V18,!35]!
add!Roberts!KJ!2011!study!to!ref!list.!Compared!to!our!findings,!the!favorable!costV
effectiveness!ratios!previously!found[19V20,!44]!are!likely!to!be!due!to!a!combination!
of! the! use! of! very! high! utility! values! (~0.97),! infrequent! surveillance! intervals! (5!
yearly)! and! less! coverage! of! the! costs! involved.! These! studies! also! used! higher!
rates! of! progression! to! cancer! under! surveillance! (~0.50%).! ! In! effect,! the! most!
favorable! estimates! were! used! to! produce! costVeffective! surveillance! findings! and!
may!not!represent!the!broader!and!recent!evidence!base.!Finally,!Rubenstein!JH!et*
al.! 2005! took! a! different! approach! to! us! with! their! hypothetical! costVeffectiveness!
study!involving!a!biomarker!testing!option.!Unlike!our!study!that!relied!on!actual!‘wet!
lab’! biomarker! data,!Rubenstein! JH!et* al.! worked! backwards! to! try! and! determine!
how!sensitive!and!specific!a! "biomarker"!would!need! to!be,!and!how!cheap,! to!be!
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cost! effective! in! surveillance.! Compared! with! their! Markov! model,! our! model! was!
more!comprehensive!in!terms!of!treatment!options.!
!
In! so!much! that! costVeffectiveness! was! clearly! improved,! our! study! suggests! that!
endoscopic! surveillance! should! be! limited! to! highVrisk! individuals.! However,!
identifying!these!high!risk!individuals!is!currently!difficult!and!there!are!no!biomarker!
based! strategies! currently! available! for! routine! clinical! practice.! Nevertheless,! if!
future!work! can! identify! a! strategy,! this!might! have! the!desired! impact! of! lowering!
costs! and! increasing! QALYs.! Biomarker! testing! also! presents! an! opportunity! for!
objective! assessment! of! risk,! and! could! replace! risk! assessment! based! on! the!
identification! of! lowVgrade! dysplasia! and! the! problems! with! variation! in!
histopathology! interpretation! for! this! diagnosis.! However,! the! appropriateness! of!
biomarker! testing,! its! efficacy! within! a! surveillance! program,! its! feasibility! and! its!
acceptance! are! yet! to! be! determined.! Further! research! involving! patients! with!
positive! biomarkers! and! additional! highVrisk! factors! such! as,! being! male,! the!
presence! of! esophagitis,! length! of! Barrett’s! esophagus! and! length! of! time! with!






The! assumptions!made! were! based! on! an! established! longVrunning! program!with!
wellVmanaged!and!clearly!audited!followVup!procedures!to!ensure!patient!adherence!




our! analysis! is! that! we! did! not! test! our! base! results! against! different! compliance!
rates!with!surveillance!scheduling.!Although!the!90%!compliance!rate!may!be!higher!
than! that!achieved! in!other!parts!of! the!world,!our! results!still!showed! ‘surveillance!
alone’!had!a! low!probability!of!being!costVeffective.!Surveillance! is! likely! to!be! less!
cost! effective! if! a! lower! compliance! is! modeled.! Finally,! although! the! UKVbased!
British! Society! of! Gastroenterology! guidelines! do! not! require! patients! to! have!
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confirmed! IM,!our! sample!only! included!patients!with! IM!and! therefore,! the! results!
are! likely! to!be!applicable! to!patients!undergoing! surveillance! in! the!US!and!other!
countries!which!define!BE!as!requiring!the!presence!of!IM.!
!
While! we! have! based! our! treatment! costs! on! a! thorough! analysis! of! treatment!
patterns!among!a! large!cohort! [38],!we!have!not! considered! the!various! treatment!




therapy! produces! predictable! regression,! or! prevents! cancer! development! [50V51],!
so! for! this!model!we! assumed!everyone!was!managed!with! proton! pump! inhibitor!
medication.!We!did!not!model!the!treatment!of!radiofrequency!ablation!for!lowVgrade!
dysplasia!as!this!is!still!an!area!of!controversy,!and!there!is!no!consensus!that!these!
patients! should! undergo! radiofrequency! ablation.! There! is! also! a! lack! of! outcome!
data!for!radiofrequency!ablation!for!lowVgrade!dysplasia!to!allow!this!approach!to!be!
modelled.!If!this!was!included,!however,!it!is!certain!that!the!costs!of!the!surveillance!
would! have! been! higher! than! our! base! results! due! to! the! cost! of! radiofrequency!
ablation!treatment!added!to!ongoing!endoscopic!surveillance.!Cost!effectiveness!for!





surveillance! program! for! several! reasons.! First,! we! used! a! twoVstage! modeling!
approach,! building! in! a! detailed! cancer! treatment! model! within! our! surveillance!
model! to!elucidate! the! current! drivers!of! cost/health!outcomes!of! various!available!
cancer! treatments! [27].! It! was! important! to! discern!what! features! of! treatment! are!
likely! to! impact! on! costs/outcomes! to! ensure! that! when! patients! undergoing!
surveillance!were! identified!with!highVgrade!dysplasia!or!adenocarcinoma,!potential!
costVefficiencies! of! surveillance! would! not! be! jeopardized! by! expensive! treatment!
options.! In! our! model,! a! proportion! of! patients! with! highVgrade! dysplasia! were!
promptly! and! actively! ‘treated’! rather! than! using! watchful! waiting,! which! reflects!
current! clinical! practice.! We! also! explored! the! potential! for! risk! stratification! to!
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influence! the! costVeffectiveness! of! surveillance.! In! addition,! we! used! updated!
epidemiological! estimates! of! cancer! progression! from! large! observational! cohort!
studies!(primary!patientVlevel!and!published!data)!both! involving!general!population!
Barrett’s! registries! and! longVterm! singleVcenter! surveillance! program! audit! reports.!
Using!populationVbased!published!estimates!on!progression!rates!and!qualityVofVlife!
enhances! the! previous! economic! evaluations! that! were! largely! reliant! on! author!
assumptions![16].!
!
The! costVeffectiveness! of! appropriate! management! strategies! for! patients! with!
Barrett’s!esophagus!must!be!considered.!Using!current!estimates!of! the!malignant!
potential! of! Barrett’s! esophagus! in! the! wider! population! versus! those! reported! in!
surveillance!program!audits,!surveillance!of!all!patients!with!nonVdysplastic!Barrett’s!
esophagus! may! not! be! costVeffective.! However,! further! work! to! identify! highVrisk!
individuals,! perhaps! in! the! future! using! a! biomarker! based! strategy,!might! enable!










Description! Estimate!used! Sensitivity!values! Source(s)!




Discount"rate"for"costs"and/or"effects" 5%" 0%,"1.5%,"3.5%" Australian"standards"
Background"mortality"rates" Life"Tables" U" [29]"Weighted"66%"men"
Annual!progression/regression!rates!(%!per!year)1!
"""Barrett’s"free"to"LGD" 0.40%" U" Sharma"2009"[52]"
"""Barrett’s"free"to"HGD" 0.10%" U" Assumption"
"""NDBE"to"Barrett’s"free"(regression)" 2.43%" 1.75%,"0.75%" Garside"2006"[35]"
"""LGD"to"NDBE"(regression)" 7.81%" 6.65%,"8.62%" Sth"Aust."data,"95%CI"beta"
"""HGD"to"EAC" 19.38%" ±20%" Sth"Aust."data"
!!!No!surveillance:! " " "
"""NDBE"to"LGD" 4.3%" 2.8%,"6.0%" Sharma"2009"[52]"
"""NDBE"to"HGD" 0.16%" 0.13%,"0.19%" de"Jonge"2010"[30]"
"""NDBE"to"EAC" 0.33%" 0.09%,"0.5%" Desai"2011"[31],"Hvid"Jensen"
2011"[22],"Sharma"2009"[52]"
"""LGD"to"HGD" 1.91%" 0.86%,"0.34%" Hvid"Jensen"2011"[22]"
"""LGD"to"EAC" 0.51%" 0.19%,"1.30%" Hvid"Jensen"2011"[22]"
!!!Under!surveillance:! " " "
"""NDBE"to"LGD" 2.94%" ±20%" Sth"Aust."data"
"""NDBE"to"HGD" 0.39%" ±20%" Sth"Aust"data"[53U54]"
"""NDBE"to"EAC" 0.05%" ±20%" Sth"Aust"data"[54U55]"
"""LGD"to"HGD" 0.93%" ±20%" Sth"Aust."data"
"""LGD"to"EAC" 0.12%" ±20%" Sth"Aust."Data"
"""Under!surveillance!plus!biomarker:!! (+ve/Uve)" " "
"""NDBE"to"LGD" 10.94%/1.47%" ±20%" 2,"Galipeau"2007"[23]"
"""NDBE"to"HGD" 1.46%/0.20%" ±20%" 2,"Galipeau"2007"[23]"
"""NDBE"to"EAC" 0.05%/0%" ±20%" Assumption"
"""LGD"to"HGD" 3.46%/0.46%" ±20%" 2,"Galipeau"2007"[23]"
"""LGD"to"ACO" 0.12%/0%" ±20%" Assumption"
Probabilities:"
"""EAC"is"T1" 0.152" U" Weighted"av"Sth"Aust/ACS"
"""EAC"is"T2" 0.228" U" Weighted"av"Sth"Aust/ACS"
"""EAC"is"T3" 0.431" U" Weighted"av"Sth"Aust/ACS"
"""EAC"is"T4" 0.052" U" Weighted"av"Sth"Aust/ACS"
"""EAC"is"DM" 0.137" U" Weighted"av"Sth"Aust/ACS"
"""EAC"is"T1"under"surveillance" 1.000" U" Sth"Aust."data,"[32]"
"""Person"tests"positive"for"3"biomarkers" 0.145" 0.102,"0.189" Galipeau"2007"[23]"
Utilities3:"
"""Background"annual"utility"" 0.895" 0.683,"0.95" Viney"2011"[33]"
"""Early"stage"EAC"(T1"or"T2)"(disutility)" U0.168" U" Sullivan"2011"[37]"
"""Late"stage"EAC"(T3"or"T4)"(disutility)" U0.235" U" Garside" 2006" Gerson" 2004"
[35U36]"
"""Distant"metastases"(disutility)" U0.550" U" de"Boer"2002"[34]"




"""Biomarker"testing"per"person" $458" $321,"$595" Sth"Aust"Hospital"costs"
"""Unit"cost"of"surveillance"endoscopy" $1,145" $802,"$1,489" Sth"Aust"Hospital"costs"




"""High"grade"dysplasia"treatment"(5"yrs)" $41,806" $29,264,"$54,348" Gordon"2011"[27]"
"""T1"cancer"(5"yrs)" $66,032" $46,222,"$85,842" Gordon"2011"[27]"
18"
"
Description! Estimate!used! Sensitivity!values! Source(s)!
"""T2"cancer"(5"yrs)" $83,187" $58,231,"$108,143" Gordon"2011"[27]"
"""T3"cancer"(5"yrs)" $82,566" $57,796,"$107,366" Gordon"2011"[27]"
"""T4"cancer"(5"yrs)" $82,938" $58,057,"$107,819" Gordon"2011"[27]"
"""Distant"metastases"(6"months)" $13,651" $9,556,"$17,746" Gordon"2011"[27]"
EAC:"esophageal"adenocarcinoma,"ACS:"Australian"Cancer"Study,"DM:"distant"metastases,"LGD:"lowUgrade"dysplasia,"HGD:"
highUgrade"dysplasia,"NDBE:"nonUdysplastic"Barrett’s"esophagus"





































1/285# ns# ns# ns#
Murphy#2005#[53]# #N.#Ireland# Retrospective# 178# 100# yes# 3.4# 613# 1/204# 0.50%# 1/30# 0.99%#
Olithselvan#2007#[54]# UK# Prospective### 121# 100# ns# 3.5# ns# 1/171# 1.41%# 1/161## ##
Switzer-Taylor#2008#
[56]# NZ# Retrospective# 212# 88# no# 3.95# 895# 1/100# 1.00%# ns# ns#
Bright#2009#[32]# Australia# Prospective# 405# ns# yes# 2.0# 776# 1/194# 0.52%# 1/129# 0.78%#
Roberts#2010#[55]# UK# Retrospective# 302# ns# ns# 2.2# ns# 1/61# 0.77%# 1/302# 0.15%#
Adjumobi#2010#[57]# USA# Retrospective# 165# ns# ns# 4.2# ns# ns# 0.00%# ns# 0.86%#
Wani#2011#[58]# USA# Prospective# 210# 100# yes# 6.2# 1364# 1/160# 0.44%# 1/46# 1.61%#



















QALYs! ∆!costs! ∆!QALYs! ICER!
No#surveillance# $5,226# 26.96# 73# 137# 12.04# ref# ref# ref#
Surveillance#alone#vs#No#surveillance# $14,659# 27.32# 105# 98# 12.19# $9,433# 0.16# $60,858#
Surveillance#with#biomarker#test2#vs#No#surveillance:# $11,087# 27.31# 103# 98# 12.19# $5,861# 0.15# $38,307#
Surveillance#with#biomarker#test2#vs#Surveillance#alone# $11,087# 27.31# 103# 98# 12.19# $3,572# 0.00# $1,946,085#
Alternative!biomarker!scenarios!vs!No!surveillance:! # # # # # # # #
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